Researchers discovered a biological signature that could help identify which triple negative breast cancers might respond to immunotherapy and other treatments.
Findings could identify aggressive breast cancers that will respond to immunotherapy
Researchers discovered a biological signature that could help identify which triple negative breast cancers might respond to immunotherapy and other treatments.